Redwood Scientific Technologies, Inc. (RSCI)
| Previous close | 1.0000 |
| Open | 1.1800 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.1800 - 1.3400 |
| 52-week range | 0.0758 - 1.6400 |
| Volume | |
| Avg. volume | 15,599 |
| Market cap | 273.597M |
| Beta (5Y monthly) | 3.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -12.1170 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireRedwood Scientific Technologies Inc. (OTC: RSCI) ("Redwood" or "the Company"), a pharmaceutical company, today announced a strategic shift in its product development priorities
Redwood Scientific Technologies Inc. (OTC: RSCI) ("Redwood" or "the Company"), a pharmaceutical company, today announced a strategic shift in its product development priorities. The New York-based firm will only focus on enhancing and expanding its nicotine replacement therapy (NRT) products, specifically TBX-FREE™ and TBX VAPE-FREE™.
- PR Newswire
Company Initiates Plans to Build Oral Thin Film Manufacturing in the USA for Its Stop Smoking and Stop Vaping Products
Redwood Scientific Technologies Inc. (OTC: RSCI) is excited to announce significant milestones achieved in the year ending 2023 and its strategic plans moving forward. The company has conveyed to the Board its confidence in its role as a developer of innovative pharmaceutical products, positioning itself for sustained success over the next 36 months. Jason Cardiff, CEO of Redwood, has initiated discussions with the executive team to establish an oral thin film manufacturing hub in the United Sta
- PR Newswire
Redwood Scientific Enters into Agreement with Jeeva Clinical Trials to Launch Clinical Effectiveness Study of its TBX-Free Oral Strips for Smoking and E-cigarette Cessation
Redwood Scientific Technologies Inc. (OTC: RSCI), ("Redwood" or "the Company"), a pioneering pharmaceutical company headquartered in New York, announced today that it has entered into an agreement with Jeeva Clinical Trials to launch a clinical effectiveness study of its TBX-Free oral strips products for smoking and e-cigarette cessation. The company has engaged top U.S. institution, George Mason University, to conduct the efficacy study on this new product.
